S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Opiant Pharmaceuticals, Inc. (OPNT)
Chart Events
Performance Outlook
| Previous Close | 14.55 |
| Open | 14.35 |
| Bid | 7.00 x 3000 |
| Ask | 17.77 x 1100 |
| Day's Range | 13.00 - 14.46 |
| 52 Week Range | 7.34 - 37.71 |
| Volume | |
| Avg. Volume | 105,524 |
| Market Cap | 66.131M |
| Beta (5Y Monthly) | 0.60 |
| PE Ratio (TTM) | 45.78 |
| EPS (TTM) | 0.31 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.75 |
- GlobeNewswire
Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
SANTA MONICA, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The meeting will be held online only and will begin at 09:00 AM PDT on June 14, 2022, as previously scheduled. The matters to be voted on
- Zacks Small Cap Research
OPNT: Positive Results for Pharmacodynamic Trial of OPNT003…
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update On May 10, 2022, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) provided additional details from the positive pharmacodynamic (PD) study of OPNT003, for which the company had announced results a couple of weeks ago. A copy of the company’s presentation on the results can be found here . This was a single center,
- GlobeNewswire
Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update. Recent highlights include: Finance Update Q1 revenues of $4.5 million; $2.2 million of revenue was attributable to the license agreement with Emergent BioSolutions, Inc. (“EBS”) for the
